Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT plus perioperative immunotherapy after chemoimmunotherapy induction in resectable stage II–IIIA NSCLC
ChiCTR2500099250Phase 2Recruiting
- Sponsor
- Union Hospital
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Union Hospital. Primary endpoint: Major pathological response rate (MPR). Started Mar 2025; status: recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500099250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099250.